Contrasting Dianthus Therapeutics (DNTH) and Its Rivals

Dianthus Therapeutics (NASDAQ:DNTH) is one of 1,004 public companies in the “Pharmaceutical preparations” industry, but how does it contrast to its competitors? We will compare Dianthus Therapeutics to related businesses based on the strength of its dividends, institutional ownership, earnings, valuation, analyst recommendations, profitability and risk.

Insider & Institutional Ownership

47.5% of Dianthus Therapeutics shares are held by institutional investors. Comparatively, 44.6% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 16.6% of Dianthus Therapeutics shares are held by insiders. Comparatively, 13.8% of shares of all “Pharmaceutical preparations” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Dianthus Therapeutics and its competitors top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Dianthus Therapeutics	$2.83 million	-$43.56 million	-4.33
Dianthus Therapeutics Competitors	$8.58 billion	$153.64 million	-3.20

Dianthus Therapeutics’ competitors have higher revenue and earnings than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a summary of recent ratings for Dianthus Therapeutics and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dianthus Therapeutics	0	0	6	1	3.14
Dianthus Therapeutics Competitors	6628	19138	45484	958	2.56

Dianthus Therapeutics presently has a consensus price target of $42.83, suggesting a potential upside of 69.57%. As a group, “Pharmaceutical preparations” companies have a potential upside of 76.35%. Given Dianthus Therapeutics’ competitors higher probable upside, analysts plainly believe Dianthus Therapeutics has less favorable growth aspects than its competitors.

Profitability

This table compares Dianthus Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Dianthus Therapeutics	N/A	-20.82%	-19.86%
Dianthus Therapeutics Competitors	-2,993.13%	-285.37%	-33.61%

Volatility and Risk

Dianthus Therapeutics has a beta of 1.83, meaning that its stock price is 83% more volatile than the S&P 500. Comparatively, Dianthus Therapeutics’ competitors have a beta of 1.00, meaning that their average stock price is 0% less volatile than the S&P 500.

Summary

Dianthus Therapeutics beats its competitors on 9 of the 13 factors compared.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.